B. Tiangco

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2–3, randomised, controlled trial

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat et al. · The Lancet Oncology · 2019 · 469 citations · Full text

Radiation Medicine, Radiation Therapy, Medicine +10

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

Adam Brufsky, Vicente Valero, B. Tiangco et al. · Breast Cancer Research and Treatment · 2012 · 127 citations

Second-line Bevacizumab-containing Therapy, Oncology, Breast Oncology +9

Human Parvovirus B19: Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion Recipients

Jeanne A. Jordan, B. Tiangco, Joseph E. Kiss et al. · Vox Sanguinis · 1998 · 121 citations

Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Lung Cancer · 2016 · 86 citations

Medicine, Pharmacology, Clinical Trials +8

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Journal of Clinical Oncology · 2013 · 83 citations

Global Phase 3, Pharmacotherapy, Pre-clinical Pharmacology +18